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Translocations involving 8q24 in Burkitt lymphoma and other
malignant lymphomas: a historical review of cytogenetics in the
light of todays knowledge
Abstract
Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and
primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However,
diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive,
mature B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL). Recently, two gene
expression studies have described a distinct molecular profile for BL, but also showed the persistence of
some cases intermediate between BL and DLBCL. An alternative approach to define BL is to consider
(cyto)genetic data, in particular chromosomal abnormalities other than the t(8;14) or its variants. In this
review the 'Mitelman Database of Chromosome Aberrations in Cancer,' harboring the majority of all
published neoplasia-related karyotypes, was explored to define a cytogenetic profile of 'true' BL. This
core subset of BL showed a very low complexity of chromosomal abnormalities with 40% of the cases
having the IG-MYC fusion as the sole abnormality. In the remaining cases, additional recurrent but
partially exclusive abnormalities included gains at chromosomes 1q, 7 and 12, and losses of 6q,
13q32-34 and 17p. Within the core subset, no differences were found between pediatric and adult
patients. In addition, the genetic profile of the core subset was significantly different from BL with an
8q24 breakpoint not affecting one of the three immunoglobulin loci, BL with a translocation involving
18q21/BCL2, 3q27/BCL6 or 11q13/BCL1, additionally to a breakpoint at 8q24/MYC, and from other
morphological types of lymphomas with an 8q24/MYC breakpoint. These groups showed a higher
cytogenetic complexity than the core subset of BL. BL without a detectable 8q24/MYC breakpoint
might be heterogeneous and deserves further studies. We suggest that, concordant with the WHO
classification to be published in 2008, the diagnosis of BL should be restricted to cases with expression
of CD10 and BCL6, absence or very weak expression of BCL2 protein, a homogeneously very high
proliferation index and a proven IG-MYC translocation without evidence of a chromosomal
translocation typical for other lymphoma entities. In addition, a high number of nonspecific cytogenetic
abnormalities should suggest need for a critical review of the diagnosis of BL.
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Burkitt lymphoma (BL) has a characteristic clinical presenta-
tion, morphology, immunophenotype and primary chromosomal
aberration, that is, the translocation t(8;14)(q24;q32) or its
variants. However, diagnostic dilemmas may arise in daily
practice due to overlap of BL with subsets of other aggressive,
mature B-cell lymphomas such as diffuse large B-cell lympho-
mas (DLBCL). Recently, two gene expression studies have
described a distinct molecular profile for BL, but also showed
the persistence of some cases intermediate between BL and
DLBCL. An alternative approach to define BL is to consider
(cyto)genetic data, in particular chromosomal abnormalities
other than the t(8;14) or its variants. In this review the ‘Mitelman
Database of Chromosome Aberrations in Cancer,’ harboring the
majority of all published neoplasia-related karyotypes, was
explored to define a cytogenetic profile of ‘true’ BL. This core
subset of BL showed a very low complexity of chromosomal
abnormalities with 40% of the cases having the IG–MYC fusion
as the sole abnormality. In the remaining cases, additional
recurrent but partially exclusive abnormalities included gains at
chromosomes 1q, 7 and 12, and losses of 6q, 13q32–34 and
17p. Within the core subset, no differences were found between
pediatric and adult patients. In addition, the genetic profile of
the core subset was significantly different from BL with an 8q24
breakpoint not affecting one of the three immunoglobulin loci,
BL with a translocation involving 18q21/BCL2, 3q27/BCL6
or 11q13/BCL1, additionally to a breakpoint at 8q24/MYC,
and from other morphological types of lymphomas with an
8q24/MYC breakpoint. These groups showed a higher cyto-
genetic complexity than the core subset of BL. BL without a
detectable 8q24/MYC breakpoint might be heterogeneous and
deserves further studies. We suggest that, concordant with the
WHO classification to be published in 2008, the diagnosis of BL
should be restricted to cases with expression of CD10 and
BCL6, absence or very weak expression of BCL2 protein, a
homogeneously very high proliferation index and a proven
IG-MYC translocation without evidence of a chromosomal
translocation typical for other lymphoma entities. In addition,
a high number of nonspecific cytogenetic abnormalities should
suggest need for a critical review of the diagnosis of BL.
Leukemia (2009) 23, 225–234; doi:10.1038/leu.2008.281;
published online 16 October 2008
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Brief history of genetics in Burkitt lymphoma
Burkitt lymphoma (BL) was first described in 1958 by Denis P
Burkitt as ‘a sarcoma involving the jaws in African children’.1
After the identification of the Epstein–Barr virus,2 BL became a
model for the exploration of chromosomal aberrations in
cancer. From their cytogenetic analyses of BL cell lines, Kohn
et al.3 observed abnormalities of C-group chromosomes. In
1972, Manolov and Manolova4 reported a marker band at the
end of chromosome 14. Zech et al.5 were the first to suggest that
a translocation event occurred between the telomeric end of the
long arm of chromosome 14 and the telomeric end of the long
arm of chromosome 8. Variant translocations towards 2p and
22q were described in BL cell lines in 1979.6,7 The molecular
targets of these translocations were discovered to be MYC
(at 8q24),8,9 and genes coding for the immunoglobulin heavy
chain (IGH at 14q32),10 kappa light chain (IGK at 2p12)11 and
lambda light chain (IGL at 22q11).12 All translocations juxtapose
the MYC gene to one of the IG enhancers, which results in
constitutive deregulation of MYC expression. Although it is
considered to be the hallmark of BL, translocation of MYC is not
specific, as it is also seen in other types of lymphomas.13
Current diagnostic dilemma
Although a correct diagnosis of classic BL can easily be made
using a combination of clinical, histological, immunopheno-
typical and genetic criteria including the presence of a
translocation involving MYC,14 problems arise when consider-
ing other B-cell Non-Hodgkin’s lymphomas (B-NHL) with one
or more overlapping features with BL. Especially the distinction
between BL and a small subset of diffuse large B-cell lymphoma
(DLBCL) with multiple characteristics of BL (for example,
morphological features, a MYC translocation and/or a very high
proliferation index) appears to be problematic.15 This distinction
has important clinical implications for treatment and prognosis,
as BL responds relatively poor to standard DLBCL therapy
(CHOP-like regimen) but excellent to high-intensity chemo-
therapy.16–18 As this distinction may be difficult using the
current diagnostic tools,19 several groups have focused on new
parameters.19–24 Recently, two comprehensive gene-expression
studies on the subject have been published, showing some
differences in outcome. In both studies, BL could be distin-
guished from other aggressive lymphomas by a distinctive gene
expression pattern, that is, the combination of expression levels
of multiple genes being able to predict a diagnosis of BL
(predictor or index). Cases with a high index were called
‘molecular BL’ and cases with a low index ‘non-molecular BL.’
According to the Molecular Mechanisms in Malignant
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Lymphomas (MMML) Network Project study,25 the greater
majority of mature aggressive B-cell lymphomas cases could
be classified as either molecular BL or DLBCL, but an
intermediate zone remained, as 48 of 219 (22%) of the cases
could not be classified, as molecular BL or non-molecular BL.
Moreover, 81% of all conventionally classified BL but also 11 of
165 (7%) morphologic DLBCL had a molecular profile of BL
(Table 1a). No real intermediate group existed in the study of the
Lymphoma/Leukemia Molecular Profiling Project (LLMPP);26
however, 7 out of 20 (35%) morphologically difficult to classify
DLBCL cases had a molecular profile of BL (Table 1b).
Furthermore, in the MMML study bcl-2 expression and BCL2
translocations were observed in 9 and 1 out of the 44 molecular
BL cases, respectively.25 From the 53 molecular BL cases of the
LLMPP study, 5 cases showed bcl2 protein expression and 3 had
a BCL2 breakpoint in addition to the MYC breakpoint.26 Both
observations are in contrast with the criteria of the WHO
classification from 2001.14 These contradictions point to the
possible utilization of additional criteria for a diagnostic
definition of these intermediate lymphomas.
Role of genetics in the diagnosis of BL
Another approach to distinguish ‘true’ BL cases from mimickers
might be the inclusion of genomic criteria in addition to the
MYC-translocation. In 1982, Berger et al.27 reported that
approximately 40% of the BL/leukemia cases have a t(8;14) or
variant translocation as the sole cytogenetic abnormality. The
lack of complex genetic alterations in addition to a MYC
translocation might therefore be suggestive for a ‘true’ BL.28,29
The presence of an additional translocation as found in other
types of B-NHL (for example, involving BCL2, BCL6 and/or
CCND1) or a complex karyotype with multiple gains and/or
losses would rather represent another type of B-NHL or a
secondary transformed lymphoma.30 This is supported by the
publication of the MMML where array based comparative
genomic hybridization (arrayCGH) was used to study genomic
copy number imbalances in addition to fluorescent in situ
hybridization (FISH) analysis for MYC, BCL2 and BCL6
translocations. In contrast to molecular BL, non-molecular BL
were characterized by a less frequent IG-MYC translocation and
by more additional genomic aberrations. ‘Intermediate’ cases
were enriched for non-IG–MYC fusions, IG–MYC fusions in
complex karyotypes and additional translocations of either
BCL2 or BCL6.25 A recent study of the LLMPP using CGH on BL
revealed that the ‘discrepant cases’ (that is, molecular BL, but
with aberrant morphology and/or immunophenotype) showed a
more complex genetic make-up, including BCL2 breakpoints as
detected by FISH.31 These observations indicate that other
genomic features than the MYC translocation status are
important to distinguish ‘true’ BL from mimickers. The aim of
this review is to define the cytogenetic profile of ‘true’ BL and to
use this profile to distinguish BL from other B-cell lymphomas
with an 8q24/MYC breakpoint.
The Mitelman database as a comprehensive cytogenetic
resource
To base our analyses on the largest available set of lymphomas
we chose the ‘Mitelman Database of Chromosome Aberrations
in Cancer’32 as our resource. The edition of the Mitelman
database (September 2007) contained 6359 B-cell malignan-
cies. Overall, 865 B-NHL with an 8q24 translocation were
selected, including 538 BL. In addition, 108 cases of morpho-
logic BL without a documented 8q24 translocation became part
of the data set. Mature ‘Burkitt’ leukemias (ALL-L3 according to
the FAB classification) were included, but not lymphomas
and leukemias derived from precursor B-cells and plasma
cell-related disorders.
Although we included series published between 19765 and
200733 and we realized that immunohistochemistry and FISH
became gradually available after 1976, we relied on the
diagnostic assignment of the cases as given through the
database. We therefore defined a core subset of BL using a
minimal set of criteria applied throughout the entire period.
These criteria are (a) morphologic diagnosis of BL, (b) presence
of a translocation between chromosome bands 8q24 (suggestive
for the MYC locus) and 2p12, 14q32 or 22q11 (suggestive for
involvement of one of the IG loci) and (c) no (additional)
breakpoint at 18q21, 3q27 or 11q13 (expected targets are BCL2,
BCL6 and CCND1, respectively). This core subset was
extensively analyzed, and compared with other B-NHL with
an 8q24 translocation as well as cases of morphologic BL that
did not fulfill all these criteria.
All karyotyping data were converted to an 862 band-specific
status map, with breakpoint and imbalance information, using
karyotype parsing software developed as part of the Progenetix
project (www.progenetix.net;34 supplementary information).
Statistical differences between genomic profiles of individual
groups were determined with the CGHMultiArray soft-
ware (http://webmath.tue.nl/mark/cgh/index.html) at a P-value
o0.05.35 The differences between groups were calculated with
the Fisher’s exact test for nominal values and the student’s t-test
for continuous variables. Although we are aware that the
mentioned cytogenetic aberrations might involve other mole-
cular targets, for readability purposes we have used molecular
terms instead of cytogenetic terms for the following cytobands:
Table 1 Summary of classification results based on gene-
expression profiling
Pathological Dx N % Molecular Dx N % Group % Total
(a) Data from MMML (N¼219)25
BL 36 16 BL 29 81 13
DLBCL 3 8 1
Intermediate 4 11 2
DLBCL 165 75 BL 11 7 5
DLBCL 115 70 53
Intermediate 39 23 18
Aggressive NOS 18 8 BL 4 22 2
DLBCL 9 50 4
Intermediate 5 28 2
(b) Data from LLMPP (N¼80)a, 26
BL 45 56 BL 44 98 55
DLBCL 1 2 1
Intermediate
DLBCLb 29 36 BL 8 28 10
DLBCL 20 69 25
Intermediate 1 3 1
Aggressive NOS 6 8 BL 1 16 1
DLBCL 5 84 6
Intermediate
Abbreviations: BL, Burkitt lymphoma; DLBCL, diffuse large B-cell
lymphomas.
aTotal of 223 previously profiled DLBCL cases were excluded.
bTwenty nine morphologically ‘difficult’ DLBCL cases with an original
diagnosis of atypical BL or Burkitt-like lymphoma but reclassified as
DLBCL by the expert panel.
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MYC for 8q24, BCL2 for 18q21, BCL6 for 3q27, CCND1 for
11q13, IGH for 14q32, IGK for 2p12 and IGL for 22q11.
Case selection and subgroup definition
The data set included 865 B-NHL with a MYC translocation
(Figure 1); 538 represented BL/leukemia and 327 cases another
type of B-NHL (Supplementary Table 1). From the 538 BL cases,
525 (98%) had a translocation of MYC towards an IG locus
(IG-MYC), the remaining 13 BL (2%) harbored a translocation of
MYC towards a non-IG locus (non-IG-MYC). Out of the 327
other B-NHL with a MYC translocation, 256 (78%) harbored
an IG-MYC translocation, while 71 cases (22%) harbored a
non-IG-MYC translocation (significance of difference with BL
Po0.0001). In addition, 108 morphologic BL cases without a
confirmed MYC translocation were included.
In addition to the MYC translocation, 621 completely
annotated translocation events were found in 380 cases. The
most common translocations involved 18q21 (BCL2, N¼ 126),
11q13 (CCND1, N¼ 35) and 3q27 (BCL6, N¼ 31), which are
commonly seen in other types of lymphoma (for example,
follicular lymphoma, mantle cell lymphoma and DLBCL). All
cases with one or more of these translocations in addition to a
MYC translocation were regarded as ‘double-hit’ (DH) lympho-
mas (N¼ 177). In line with the new WHO classification of
2008, we used the expression DH throughout this manuscript
and defined this as any kind of 8q24/MYC translocation plus any
translocation involving 18q21/BCL2, 11q13/CCND1 or 3q27/
BCL6. Nevertheless, we realize that the expression ‘double-hit’
is not uniformly used by authors and moreover might not fully
cover the heterogeneity of this group. It might even be more
appropriate to use the expression ‘MYC plus’ where behind
‘plus’ the specific second oncogene targeted could be men-
tioned (for example, ‘MYC plus BCL2’). Fifty-three of the 177
DH lymphomas (29%) had a diagnosis of BL (44 IG-MYC and 9
non-IG-MYC cases) and 124 (71%) had a diagnosis of another
type of B-NHL (76 IG-MYC and 48 non-IG-MYC cases).
Out of the total data set of 973 cases, age and gender were
available for 808 (83%) and 932 (96%) cases, respectively, with
gender being derived from karyotype information in a small
subset of cases. When the cases were divided into five age
cohorts (0–15, 16–30, 31–45, 46–60, 61–89 years), the
percentage of morphological BL cases with IG-MYC decreased
with age, while the percentage of DH BL cases and the other
B-NHL cases (both IG-MYC and non-IG-MYC) increased with
age. These differences were underscored by the age distributions
of the single subgroups (Figure 2).
Definition of a core subset of BLFfew cytogenetic
differences between children and adults
Out of the 973 cases, 481 cases fulfilled our criteria for the core
subset of BL (Figure 1; BL IG-MYC single hit): a morphological
diagnosis of BL, a cytogenetic detection of an IG-MYC
translocation and exclusion of a translocation of BCL2, BCL6
and/or CCND1. The distribution over the different age cohorts
was very similar to that of population-based studies with almost
half of patients being under the age of 15 years and a strong
All B-NHL
 t(MYC)
865 cases
BL
t(MYC)
538 cases 
Other B-NHL
t(MYC)
327 cases
Other B-NHL 
non-IG-MYC
71 cases 
(22%)
Other B-NHL 
IG-MYC SH
256 cases
(78%)
BL
non-IG-MYC
13 cases
(2%)
BL 
IG-MYC
525 cases
(98%)
BL
non-IG-MYC DH
9 cases 
(69%)
BL
non-IG-MYC SH
4 cases 
(31%)
BL 
IG-MYC DH
44 cases 
(8%)
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IG-MYC SH 
481 cases
(92%)
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205 cases
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215 cases
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61 cases
Other B-NHL
IG-MYC DH
76 cases 
(30%)
Other B-NHL
IG-MYC SH
180 cases
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Other B-NHL
non-IG-MYC DH
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(66%)
Other B-NHL
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23 cases 
(34%)
BL without 
t(MYC)
108 cases
BL without 
t(MYC)
108 cases
Figure 1 Flow chart of all cases from the Mitelman database.
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male preponderance.36–38 As pediatric BL is thought to be
prototypic for ‘true’ BL, we further limited the core subset to the
205 pediatric cases (age p15 years). Although even in this
group the possibility of a misdiagnosis can not be excluded, the
few potentially misdiagnosed cases should not have a strong
impact on the overall cytogenetic profile. The mean age of this
pediatric subset was 8 years and the majority of patients were
male (74%). One hundred eighty-five patients (90%) had a
classical t(8;14), 13 patients (6.5%) had a t(8;22) and 7 (3.5%) a
t(2;8) variant translocation. In addition to this translocation, few
other cytogenetic aberrations were found. Numerical imbal-
ances and additional, non-recurrent translocations (not involving
BCL2, BCL6 or CCND1) were detected in 122 and 36 of the
205 cases (60 and 18%, respectively). The most common
aberrations (Figure 3) were singular events, with 87% of cases
having 0–2 imbalances (0: 40%, 1: 33%, 2: 16% and 42
imbalances: 11%). As a surrogate for genomic complexity, we
calculated the complexity score per case in accordance with the
publication of the MMML.25 In short, every non-continuous
imbalance per chromosome was counted per case with an
additional separation at chromosomal centromeres. Only
imbalances were counted, whereas balanced translocations
(copy number neutral) had no impact on the complexity score.
Although the data cannot be directly compared to the complex-
ity values from the MMML, as different techniques were used,
our core BL subset also showed a very low complexity score as
published for the molecular BL cases.25 In addition, this
complexity score linearly correlated with the number of aberrant
chromosomes or cytobands (Supplementary Figure 1).
In the adult group (415 years), the mean age was 35 years
and again the majority of patients were male (75%). Compared
with the pediatric group, more adult cases harbored a variant
MYC translocation (22 versus 10%, P¼ 0.0003). The most
common numerical aberrations were almost identical except for
a higher prevalence of gain of 8q in the adult group (Figure 3).
Both the average number of imbalances (77% of adults having
0–2 numerical imbalances) and the genomic complexity score
(Figure 4b) were very similar for children and adults. This
supports recent studies,25,26,39 suggesting that from a cyto-
genetic and gene expression point of view, BL in children and
adults is the same disease. The differences between children and
adults found by others in smaller cohorts36,40,41 may represent
the inclusion of BL mimickers. In light of these results and also
the fact that the genetic profile of the patients with no data on
age available were almost identical, we extended our core
subset to BL IG-MYC single hit samples independent of patient
age (Figure 3). The validity of our criteria is also supported by
the absence of significant differences in complexity and the
proportion of cases diagnosed as BL or another type of B-NHL,
when we compared cases published before (N¼ 280) and after
1994 (N¼ 201) (Supplementary Figure 2).
The most common aberrations in this core subset (occurring
in 44% of the cases) were copy number gains involving 1q, 7
and 12, and losses involving 6q, 13q32–34 and 17p (Figure 5).
To investigate co-occurrence of the different cytogenetic
imbalances, we performed cluster analyses on all 696 cases
with imbalances (Figure 4c; Supplementary Figure 3). As a
compromise between cross-talk between neighboring intervals
and resolution, we used a reduced cluster matrix (86 regions).
Figure 4c shows that the core BL clusters together. Focusing on
core BL cases (Supplementary Figure 4), it seemed that gain of
1q is associated with lack of other recurrent abnormalities, with
a mostly random scattering of abnormalities in the other cases.
The cytogenetic profile of the BL core subset is different from
the cytogenetic profile of other B-NHL cases with a MYC
translocation
A MYC translocation is not specific for BL,12 and is also seen in
a subset of morphological DLBCL,42–44 follicular lymphoma45
or mantle cell lymphoma.46 We found 327 of such cases in our
data set, with the majority having a diagnosis of DLBCL
(N¼ 135; 41%), B-cell lymphoma-NOS (N¼ 79; 24%) and
follicular lymphoma (N¼ 52; 16%) (Supplementary Table 1).
Apart from the DLBCL cases, these cases are commonly thought
to represent transformed disease and therefore may harbor a
non-IG-MYC breakpoint or additional translocations (for exam-
ple, involving BCL2 or CCND1), as well as a higher number of
numerical aberrations.47–50 Indeed, the complexity score was
BL IG-MYC SH
BL IG-MYC DH
BL non-IG-MYC
BL without MYC
other B-NHL IG-MYC
other B-NHL non-IG-MYC
0 20 40 60 80
age
0-15 16-30 31-45 46-60 61-89
0.0
0.2
0.4
0.6
0.8
1.0
Figure 2 Age distributions of the different subgroups. (a) Box and Whisker plot with median and lower and upper quartiles. (b) Relative incidence
of the different disorders in the different age cohorts. For colors, see panel a.
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much higher in the other B-NHL cases (Figure 4a; significance of
difference Po0.0001) and gains of 7, 11p, 11q11–22, 12, 18
and X and loss of 4q, 6q13–27, 9, 10p, 15, 17p13 and 17q11–23
were more common compared with the BL core subset
(Figure 5). In addition, patients were older (mean 50 versus
23.5 years, Po0.0001; Figure 2), and the male/female ratio was
lower (Supplementary Table 3). These differences persisted
when limiting the group to cases with a morphological diagnosis
of DLBCL (data not shown).
Morphologic BL without a reported MYC translocation show
genetic differences from the core subset
Although in the WHO classification a MYC translocation is a
prerequisite for the diagnosis of BL, cases with typical
phenotype (morphology and immunohistochemistry) and a very
high proliferation index but lacking a MYC translocation often
are diagnosed as BL. The precise classification and treatment of
these cases is under ongoing discussion. Some authors suggest
that such cases should by definition be classified (and treated) as
DLBCL,41 but others claim that such cases behave more
aggressively than DLBCL and would benefit from more
aggressive therapy.20 We compared this group (N¼ 108) with
the core subset. The genomic complexity was higher (mean 4.5
versus 1.7 Po0.0001; Figure 4a). Specifically, gain of 6p, 7p,
11p and 18 and loss of 9, 14q32, 16 and 22 were more common
(Figure 5). In addition, this group showed a higher mean age of
29 years (Figure 2, P¼ 0.014), and the male/female ratio was
lower than that in the core subset (Supplementary Table 2). We
hypothesize that these 8q24 translocation negative BL cases
might represent three subgroups: (a) cases in which the original
karyotyping missed a MYC translocation, (b) cases that harbored
a different mechanism by which MYC can be overexpressed or
(c) cases that were misdiagnosed as BL. In case of (a) or (b),
molecular techniques (for example, FISH) could have provided
additional information. The most important conclusion could
therefore be that this group should prospectively be reduced by
applying strict immunohistochemical criteria in combination
with proper additional molecular techniques, to detect hidden
MYC translocations and to exclude additional breakpoints
involving BCL2, BCL6 or CCND1. The final classification (and
treatment) of the remaining cases without any indication of a
MYC translocation as either BL, DLBCL or a separate entity
should be subject of further research.
BL with a non-IG-MYC translocation (BL non-IG-MYC) is a
rare entity and is different from the core subset
The activation of MYC by juxtaposition towards one of the IG
loci is considered the canonical starting point of BL and
therefore a condition sine qua non for the diagnosis. Other
mechanisms such as amplification or deregulation by juxtaposi-
tion of MYC with other genes might also lead to MYC
overexpression and as a result a BL-like morphology.51,52
Non-IG-MYC translocation may occur as a secondary event
(for example, in follicular lymphoma), resulting in a transformed
lymphoma with a BL-like morphology.53 Although the numbers
were small, we compared the genetic profile of the 13 BL with a
non-IG-MYC breakpoint with that of the core subset. The
genomic complexity of the 13 BL non-IG-MYC cases was much
30%
0%
30%
30%
0%
30%
30%
0%
30%
30%
0%
30%
30%
0%
30%
30%
0%
30%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1819 202122 X Y
BL IG-MYC SH - pediatric cases (n=205)
BL IG-MYC SH - adult cases (n=215)
BL IG-MYC SH - no age information (n=61)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1819 202122 X Y
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1819 202122 X Y
Figure 3 Histogram of genetic aberrations in core Burkitt lymphoma (BL). Histograms for numerical imbalances in pediatric (a), adult (b) and
patients of unknown age (c) from the core subset of BL at a virtual 862 band resolution. Green/light grey: gain; red/dark grey: loss.
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higher (mean 4.6 versus 1.7 P¼ 0.0003; Figure 4a) and gain of
7p and 8q22–23 and loss of 8q24, 13q32–34 and X were more
common (Figure 5). In addition, the age distribution was skewed
towards a higher age (Figure 2) and there was a female
preponderance (Supplementary Table 2).
Our data show that a non-IG-MYC translocation is extremely
rare in cases morphologically diagnosed as BL. This corroborates
the publication of Bertrand et al.53 on the largest series (N¼ 17) of
such B-NHL, of which only one case had a BL morphology. These
authors suggested that the non-IG-MYC is a secondary event. In
line with this conclusion, 9 out of our 13 cases (69%) harbored
two translocations involving MYC and also BCL2, BCL6 or
CCND1 (to be discussed below). Therefore, we suggest that BL
non-IG-MYC cases should not be considered as ‘true’ BL.
Double-hit BL (BL IG-MYC DH) should not be considered as
‘true’ BL
In 44 out of the 525 BL cases with an IG-MYC breakpoint, other
recurrent translocations were found in addition to the MYC-
translocation. We found 31 breakpoints at BCL2 (70% of all
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Figure 4 Complexity score and cluster analysis of the different subgroups. (a) Shows the imbalance complexity scores for the main subgroups
analyzed and (b) for the three age subgroups of the core subset. Box and Whisker plots with median values, lower and higher quartiles. (c) Shows
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cases), 15 at BCL6 (34%) and 5 at CCND1 (11%), 6 cases (14%)
having triple hits for MYC, BCL2 and BCL6. As described in the
previous paragraph, the IG-MYC translocation in such cases is
thought to be the second hit. Various authors have already
suggested that such DH BL cases should be considered a
separate entity from ‘true’ BL.30,54,55
When comparing the 44 BL IG-MYC DH cases with the core
subset, they appeared to be two separate entities. DH BL
patients were much older (mean 51 years, Po0.0001, Figure 2),
very much similar to the other B-NHL group. Also the genomic
complexity of the DH cases was much higher than that in the
core subset (mean 5.4 versus 1.7, Po0.0001; Figure 4a). Gains
of 7, 8, 11, 12, 18, 20 and X and loss of 3q27–29, 6q and 15q26
were significantly more common in the DH subgroup (Figure 5).
The overlap between BL IG-MYC DH and other B-NHL cases
was supported by the fact that DHs were also very frequent in
the group of other B-NHL (124/327, 38%). These observations
support the available clinical data on this type of lymphoma.
The patients have a very aggressive disease that is refractory to
current chemotherapeutic treatment. Overall survival is very
short, even if treated with high-intensity chemotherapy as used
for BL.56
Another intriguing observation is that a variant MYC
translocation towards 2p or 22q occurred more often in DH
lymphomas (55%), compared with the core subset (16%).
According to Au et al.,57 this supports the hypothesis that the
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Figure 5 Genetic aberrations in all subgroups. Histogram of genetic aberrations of all different subgroups at a virtual 862 band resolution (a–e).
Green/light grey: gain; red/dark grey: loss.
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IG-MYC translocation is a secondary event, as one IGH locus is
already occupied by the primary translocation (that is, t(11;14)
or t(14;18)) and the other IGH allele should remain functional
for B-cell receptor signaling.
The LLMPP study25 suggested that at least some DH
lymphomas may have a molecular profile that is very similar
to that of ‘true’ BL. A larger series of such lymphomas has to be
studied independently from the designed BL predictors to know
whether these lymphomas really are similar to ‘true’ BL or not.
For now, there are strong indications that DH BL should be
considered a separate disease from ‘true’ BL. In the new WHO
classification of 2008, it is advised that these cases are labeled
as a separate group ‘B-cell lymphoma with features intermediate
between DLBCL and BL’.
Summary and conclusions
In view of the therapeutic and prognostic consequences, the
diagnosis of BL should be made with the highest level of
certainty. So far this is done with conventional tools, including
clinical aspects.14 With these techniques, the distinction is still
hard to make in a subset of cases, especially in the ‘gray-zone’
between BL and DLBCL, and additional criteria might be of use.
In this review, we studied the cytogenetic profile of ‘true’ BL
using the unique, comprehensive collection of cytogenetic data
in the ‘Mitelman database.’32 We defined a core subset of BL,
that is, lymphomas that were registered as such on a
morphological basis, contained an IG-MYC translocation and
did not harbor chromosomal translocations of the BCL2, BCL6
or CCND1 loci. As a proof of principle, we compared the
cytogenetic profile of this core subset with those of other B-NHL
with a MYC breakpoint, with BL cases without a MYC
breakpoint, with BL cases with a non-IG-MYC breakpoint and
with DH BL cases. The validity of the used criteria for BL was
underscored by the absence of any significant increase in the
genomic complexity score with age as well as the similarity for
cases published before and after the introduction of the REAL
classification in 1994. Interestingly, lack of differences in
genomic complexity between pediatric and adult cases was
independently found by the MMML39 and LLMPP.31
We demonstrated that these core BL cases are obviously
different from other B-NHL cases with a MYC translocation, as
the latter harbor more and also other genetic aberrations than
‘true’ BL. In ‘true’ BL gains of 1q, 7 and 12 are found as common
recurring events, while (the even less frequent) losses mostly
involve 6q, 17p as well as 13q32–q34. Besides differences in
cytogenetic complexity and pattern, the available epidemiologi-
cal data (age and gender distribution) also differed between the
two groups. Obviously, morphological criteria remain essential to
distinguish BL from other lymphomas. Without availability of
gene expression-profiling data, cases with an IG–MYC fusion
without evidence of a DH should not be considered as BL, unless
indicated by histological appearance. This is supported by our
analysis of all 661 IG-MYC single hit lymphoma cases, in which
21% of the 475 cases with a complexity score of 0–2 had an
original diagnosis other than BL (Figure 6; Supplementary Figure
5). On the other hand, we are aware of the fact that this study
cannot give any guideline to definitely identify the rare individual
lymphomas that are morphologically different from BL but
nevertheless should be considered as molecular BL based on
advanced molecular profiling.
Furthermore, we conclude that both DH BL cases as well as
the extremely rare BL cases with a non-IG-MYC breakpoint
(which in fact mainly represent DH lymphomas) should be
separated from ‘true’ BL, as both their genomic and epidemio-
logical profile are much more similar to other types of B-NHL.
This is supported by the MMML data on gene expression and by
clinical data showing that such patients have a very aggressive
disease that is hardly curable with conventional or high-intensity
chemotherapeutic regimens. The awareness on such DH cases
is needed especially in older patients, as almost one-third of all
cases diagnosed as BL in the database above the age of 60 years
appeared to be a DH BL.
There are practical consequences from this review. While
lacking the molecular resolution of FISH methods, cytogenetic
analysis has the great advantage of giving a ‘bird’s eye’ overview
of the many relevant genetic abnormalities in BL, that is, the
partner of the MYC locus, the presence or absence of additional
translocations and presence or absence and number of other
structural abnormalities. Therefore, the authors strongly advise
to submit material of any lymphoma suspicious for BL or
mimicking diseases for conventional cytogenetic analysis by
metaphase karyotyping. In addition, a simple MYC segregation
FISH test should be carried out in all cases. More elaborate FISH
tests for MYC, IG loci and also BCL2, BCL6 and eventually also
CCND1, should be carried out in all BL with some abnormality
in morphology or immunohistochemistry for CD5, CD10, BCL2,
BCL6 or Ki-67. The use of fewer tests should be strictly restricted
to pediatric patientso15 year. Another point to consider is that,
although a FISH split signal assay with two probes flanking the
MYC gene is the most sensitive and fast assay for detection of
MYC breakpoints, it is not able to distinguish IG-MYC from non-
IG–MYC fusions and does not cover all MYC breakpoints, that
is, far 50 and 30 breakpoints as well as small insertions are not
detected.58,59 Furthermore, the steady increase in the age of
lymphomas that mimic BL strongly emphasizes that there is no
distinct age at which a pathologist can safely make a diagnosis
of BL without any ancillary cytogenetic or molecular studies.
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Figure 6 Morphology versus imbalance complexity in IG-MYC single
hit lymphomas. All lymphoma cases with an IG-MYC breakpoint but
no 18q21, 3q27 or 11q13 breakpoint were analyzed for imbalance
complexity and original histological diagnosis. A histological diag-
nosis of BL (red/dark grey bars) is associated with a lower complexity
and other diagnoses (blue/light grey bars) are gradually increasing in
cases with a higher complexity.
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